Genmab A/S has reported positive Phase 3 results for rinatabart sesutecan, also known as Rina-S, demonstrating a 57% reduction in the relative hazard of death and a 71% reduction in the relative hazard of disease progression or death compared with chemotherapy in patients with platinum-resistant ovarian cancer. The global RAINFOL-02 study met its primary progression-free survival endpoint and key secondary overall survival endpoint, delivering statistically significant findings in a difficult-to-treat patient population. The results provide pivotal evidence supporting further regulatory development of the investigational antibody-drug conjugate, potentially expanding treatment options for patients whose ovarian cancer no longer responds adequately to platinum-based chemotherapy.
The findings are especially significant because the study enrolled patients regardless of folate receptor alpha expression, potentially supporting treatment across a broader population than some existing targeted therapies. Genmab plans to discuss the results with regulatory authorities worldwide, although detailed survival durations, response rates and comprehensive safety findings have not yet been disclosed.
How did Genmab’s Rina-S perform against chemotherapy in the Phase 3 RAINFOL-02 trial?
The randomized, open-label, multicenter RAINFOL-02 study evaluated Rina-S against investigator’s choice chemotherapy in patients with platinum-resistant ovarian cancer. The intent-to-treat analysis included 584 randomized participants, who received either Rina-S or one of four chemotherapy options: paclitaxel, topotecan, pegylated liposomal doxorubicin or gemcitabine.
Rina-S was administered at 120 mg/m² on Day 1 of each three-week treatment cycle. The primary endpoint assessed investigator-determined progression-free survival, measuring how long patients remained alive without cancer progression, while overall survival and objective response rate were among the key secondary endpoints.
In the intent-to-treat population, Rina-S achieved a progression-free survival hazard ratio of 0.29 compared with chemotherapy, with a 95% confidence interval of 0.23 to 0.37 and a p-value below 0.0001. This corresponds to a 71% lower relative hazard of disease progression or death during the assessment period.
The study also demonstrated statistically significant progression-free survival benefits in its primary analysis set of 492 patients. In this population, Rina-S achieved a hazard ratio of 0.33, corresponding to a 67% lower relative hazard of progression or death, with a p-value below 0.0001.
These findings provide consistent evidence of treatment benefit across the two prespecified analysis populations. However, a hazard reduction describes the relative difference in event rates over time rather than the absolute percentage of patients who avoided disease progression.
Genmab has not yet reported the median progression-free survival achieved by either treatment group. Those figures will be important for understanding the absolute duration of benefit and helping clinicians evaluate how the results might translate into patient care.
Why is the 57% reduction in death hazard particularly important for ovarian cancer treatment?
The RAINFOL-02 trial also met its key secondary endpoint of overall survival, an especially meaningful finding because prolonging survival remains a central objective of treatment for recurrent ovarian cancer.
In the intent-to-treat population, Rina-S achieved an overall survival hazard ratio of 0.43 compared with chemotherapy. The result corresponds to a 57% lower relative hazard of death, with a 95% confidence interval of 0.31 to 0.59 and a p-value below 0.0001.
The primary analysis set produced a similarly favorable result, with an overall survival hazard ratio of 0.44. This represents a 56% lower relative hazard of death, with a confidence interval of 0.31 to 0.63 and a p-value below 0.0001.
The consistency of these findings strengthens the clinical significance of the announcement. Progression-free survival improvements can indicate treatment activity, but an accompanying overall survival benefit provides more direct evidence that patients may live longer with the investigational therapy.
Nevertheless, the reported 57% figure should not be interpreted as a 57% absolute reduction in mortality or an increase in life expectancy of the same magnitude. The company has not disclosed median overall survival or absolute survival probabilities, preventing a complete assessment of the number of additional months patients may gain.
Angeles Alvarez Secord, professor of obstetrics and gynecology at Duke Cancer Institute and a lead investigator for the Gynecologic Oncology Group, indicated that the results could represent an important treatment advance for patients with platinum-resistant ovarian cancer. She emphasized the significance of achieving substantial survival benefits without restricting eligibility to a narrow folate receptor alpha expression subgroup.
How could Rina-S’s folate receptor alpha mechanism expand targeted ovarian cancer treatment?
Rina-S is an investigational antibody-drug conjugate designed to target folate receptor alpha, a cell-surface protein expressed in varying amounts by ovarian cancer cells. Antibody-drug conjugates combine a tumor-targeting antibody with a potent anticancer payload, aiming to deliver cytotoxic activity to cells expressing the target.
The Rina-S antibody is linked to a topoisomerase I inhibitor, which interferes with processes required for DNA replication and repair. By directing this payload toward folate receptor alpha-expressing tumor cells, the treatment is intended to produce antitumor activity through a targeted delivery mechanism.
Folate receptor alpha is already an established therapeutic target in ovarian cancer. However, expression levels vary between tumors, and some targeted treatments require patients to meet specific biomarker thresholds before receiving therapy.
The RAINFOL-02 findings are notable because the intent-to-treat analysis included patients regardless of folate receptor alpha expression level or previous treatment with mirvetuximab, another folate receptor alpha-directed therapy.
The primary analysis set included 492 patients and incorporated a requirement that those with high folate receptor alpha expression, defined as at least 75% of tumor cells showing 2+ staining, must previously have received mirvetuximab.
Demonstrating favorable results in both populations suggests that Rina-S may have potential across different treatment histories and biomarker categories. However, the company has not yet disclosed detailed efficacy outcomes for every folate receptor alpha expression subgroup.
Further analyses will therefore be necessary to determine whether treatment benefit is consistent among patients with low, intermediate and high receptor expression. These findings could influence future prescribing criteria, companion diagnostic requirements and the treatment’s eventual position in clinical practice.
What do the Phase 3 findings mean for patients with platinum-resistant ovarian cancer?
Platinum-resistant ovarian cancer generally refers to disease that progresses or recurs within six months after platinum-based chemotherapy. Patients in this category often face limited treatment options and may require sequential therapies as their cancer becomes increasingly difficult to control.
Available approaches include single-agent chemotherapy and selected targeted therapies, depending on previous treatment exposure, tumor characteristics and individual clinical circumstances. However, treatment responses can be limited, while adverse effects and declining physical condition may restrict the ability to continue therapy.
The clinical importance of Rina-S lies in its potential to improve both the duration of disease control and overall survival relative to commonly used chemotherapy options. The successful Phase 3 findings suggest that an antibody-drug conjugate targeting folate receptor alpha could offer meaningful benefits in this difficult treatment setting.
The trial’s inclusion of patients regardless of receptor expression is another important distinction. If subsequent analyses confirm broad activity and regulators approve an appropriately inclusive indication, more patients could potentially qualify for treatment without the same expression requirements applied to certain existing therapies.
However, the open-label design introduces potential limitations when evaluating investigator-assessed progression-free survival. Overall survival is less susceptible to assessment bias, making the statistically significant survival finding particularly important.
The study also includes progression-free survival assessment by blinded independent central review, which should provide additional information about the robustness of the primary efficacy result once detailed findings are presented.
What did Genmab report about Rina-S safety and treatment tolerability?
Genmab reported that Rina-S’s observed safety profile was consistent with previous clinical experience and that investigators identified no new safety signals or unexpected safety concerns during RAINFOL-02.
This preliminary assessment is encouraging, particularly because patients with recurrent ovarian cancer may already have experienced substantial toxicity from previous chemotherapy regimens.
Nevertheless, the announcement did not provide detailed rates of treatment-emergent adverse events, severe toxicities, dose reductions, treatment discontinuations or treatment-related deaths. Without these data, it is not yet possible to make a comprehensive comparison of Rina-S’s tolerability against the chemotherapy control group.
Antibody-drug conjugates can produce adverse effects related to their cytotoxic payloads and other treatment characteristics. Potential risks require evaluation according to the specific medicine rather than assumptions based on the broader drug class.
Detailed safety analyses will therefore be important for assessing whether the survival benefits are accompanied by manageable toxicity, particularly among heavily pretreated patients or those with additional medical complications.
What comes next for Genmab as Rina-S advances toward regulatory discussions?
Genmab plans to engage with regulatory authorities worldwide to determine potential next steps for Rina-S in platinum-resistant ovarian cancer. The company also intends to submit the detailed RAINFOL-02 findings for presentation at a future medical conference.
Chief executive officer Jan van de Winkel indicated that the positive results strengthen Genmab’s confidence in Rina-S and support its ambition to expand its position in gynecologic oncology. The company is pursuing a broader development strategy designed to evaluate the antibody-drug conjugate across several cancer types and treatment settings.
Beyond RAINFOL-02, the clinical program includes Phase 3 studies in recurrent or progressive endometrial cancer, platinum-sensitive ovarian cancer maintenance therapy, second-line platinum-sensitive ovarian cancer and first-line ovarian cancer maintenance therapy.
Additional studies are evaluating Rina-S in non-small cell lung cancer and advanced gastrointestinal cancers, potentially broadening its therapeutic applications if further clinical benefits are demonstrated.
However, successful results in platinum-resistant ovarian cancer do not establish effectiveness in other tumor types. Each indication will require independent evidence addressing efficacy, safety and an appropriate balance of potential benefits and risks.
Genmab has scheduled an investor update for October 28, when additional discussion of the RAINFOL-02 program is expected. The company has not yet announced a definitive regulatory submission date or approval timeline for the ovarian cancer indication.
The Phase 3 results represent an important milestone because they demonstrate statistically significant improvements in both disease control and overall survival against chemotherapy. Yet the complete clinical picture will depend on forthcoming survival durations, subgroup analyses, objective response rates and detailed safety findings.
If these results withstand full scientific and regulatory evaluation, Rina-S could become an important additional treatment option for patients with platinum-resistant ovarian cancer. Until a regulatory decision is reached, it remains an investigational therapy whose promising pivotal findings require comprehensive review.
